Risk Assessment After a Severe Hospital-Acquired Infection Associated With Carbapenemase-Producing Pseudomonas aeruginosa.
Aged
Bacterial Proteins
Carbapenems
/ pharmacology
Cross Infection
/ microbiology
Disease Outbreaks
Environmental Microbiology
Female
Humans
Male
Middle Aged
Pseudomonas Infections
/ microbiology
Pseudomonas aeruginosa
/ drug effects
Retrospective Studies
Risk Assessment
beta-Lactam Resistance
beta-Lactamases
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
entrez:
16
2
2019
pubmed:
16
2
2019
medline:
4
12
2019
Statut:
epublish
Résumé
Resistance of gram-negative bacilli to carbapenems is rapidly emerging worldwide. In 2016, the World Health Organization defined the hospital-built environment as a core component of infection prevention and control programs. The hospital-built environment has recently been reported as a source for outbreaks and sporadic transmission events of carbapenemase-producing gram-negative bacilli from the environment to patients. To assess risk after the identification of an unexpected, severe, and lethal hospital-acquired infection caused by carbapenemase-producing Pseudomonas aeruginosa in a carbapenemase-low endemic setting. A case series study in which a risk assessment was performed on all 11 patients admitted to the combined cardiothoracic surgery and pulmonary diseases ward and the hospital-built environment in the Radboud University Medical Center, the Netherlands, in February 2018. Water and aerosols containing carbapenemase-producing (Verona integron-mediated metallo-β-lactamase [VIM]) P aeruginosa. Colonization and/or infection of patients and/or contamination of the environment after the detection of 1 patient infected with carbapenemase-producing (VIM) P aeruginosa. A total of 5 men (age range, 60-84 years) and 6 women (age range, 55-74 years) were admitted to the combined cardiothoracic surgery and pulmonary diseases ward. The risk assessment was performed after carbapenemase-producing (VIM) P aeruginosa was unexpectedly detected in a man in his early 60s, who had undergone a left-sided pneumonectomy and adjuvant radiotherapy. No additional cases (colonization or infection) of carbapenemase-producing (VIM) P aeruginosa were detected. Plausible transmission of carbapenemase-producing P aeruginosa from the hospital environment to the patient via the air was confirmed by whole-genome sequencing, which proved the relation of Pseudomonas strains from the patient, the shower drains in 8 patient rooms, 1 sink, and an air sample. This study suggests that rethinking the hospital-built environment, including shower drains and the sewage system, will be crucial for the prevention of severe and potential lethal hospital-acquired infections.
Identifiants
pubmed: 30768189
pii: 2724770
doi: 10.1001/jamanetworkopen.2018.7665
pmc: PMC6484879
doi:
Substances chimiques
Bacterial Proteins
0
Carbapenems
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e187665Commentaires et corrections
Type : CommentIn
Références
Antimicrob Resist Infect Control. 2017 Jun 10;6:59
pubmed: 28616203
Clin Infect Dis. 2017 May 15;64(10):1435-1444
pubmed: 28200000
Clin Infect Dis. 2018 Jul 2;67(2):171-178
pubmed: 29409044
Lancet Infect Dis. 2011 May;11(5):355-62
pubmed: 21478057
Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1463-8
pubmed: 27259712
J Antimicrob Chemother. 2012 Nov;67(11):2640-4
pubmed: 22782487
Antimicrob Resist Infect Control. 2017 Nov 15;6:113
pubmed: 29163939
J Hosp Infect. 2018 Mar;98(3):275-281
pubmed: 29104124
MMWR Morb Mortal Wkly Rep. 2018 Jun 15;67(23):668-669
pubmed: 29902165
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
mBio. 2018 Feb 6;9(1):
pubmed: 29437920
Bioinformatics. 2015 Sep 1;31(17):2877-8
pubmed: 25913206
Biofouling. 2011 Oct;27(9):1017-32
pubmed: 22011093
Ophthalmic Epidemiol. 2011 Jun;18(3):99-102
pubmed: 21609237
Water Res. 2018 Mar 1;130:47-57
pubmed: 29197756
Lancet Infect Dis. 2018 Mar;18(3):e99-e106
pubmed: 29102325
Infect Control Hosp Epidemiol. 2018 Nov;39(11):1307-1315
pubmed: 30284524